Status: Recruiting
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Participants needed: 188
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Updated: Feb 11, 2025Locations: 1
Eligibility criteria
Age ≥ 18 at the time of screening; [+4]
Major surgery within 4 weeks of the first dose of study treatment. [+2]